Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PLRX
stocks logo

PLRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.383
-53.34%
--
--
-0.477
-48.19%
--
--
-0.500
-29.58%
Estimates Revision
The market is revising Upward the revenue expectations for Pliant Therapeutics, Inc. (PLRX) for FY2025, with the revenue forecasts being adjusted by 11.11% over the past three months. During the same period, the stock price has changed by -29.57%.
Revenue Estimates for FY2025
Revise Upward
up Image
+11.11%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-14.63%
In Past 3 Month
Stock Price
Go Down
down Image
-29.57%
In Past 3 Month
Wall Street analysts forecast PLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLRX is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast PLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLRX is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
1 Sell
Hold
Current: 1.310
sliders
Low
2.00
Averages
3.00
High
4.00
Current: 1.310
sliders
Low
2.00
Averages
3.00
High
4.00
Citi
David Lebowitz
Neutral
maintain
2025-08-10
Reason
Citi
David Lebowitz
Price Target
2025-08-10
maintain
Neutral
Reason
Citi analyst David Lebowitz raised the firm's price target on Pliant Therapeutics to $1.70 from $1.50 and keeps a Neutral rating on the shares post the Q2 report. The company largely completed its restructuring during the quarter but the path forward bexotegrast remains unclear, the analyst tells investors in a research note.
Piper Sandler
Yasmeen Rahimi
Overweight
downgrade
$17 -> $4
2025-08-08
Reason
Piper Sandler
Yasmeen Rahimi
Price Target
$17 -> $4
2025-08-08
downgrade
Overweight
Reason
Piper Sandler analyst Yasmeen Rahimi lowered the firm's price target on Pliant Therapeutics to $4 from $17 and keeps an Overweight rating on the shares. The firm cites cash per share as there is uncertainty regarding the path forward in oncology. Piper notes that at Pliant's Q2 update, management reiterated that bexotegrast development in IPF has been discontinued following a full analysis of safety/efficacy from Phase 2b/3 BEACON-IPF with full results to be submitted for a future publication.
HC Wainwright & Co.
Ed Arce
Hold
Reiterates
n/a
2025-03-18
Reason
HC Wainwright & Co.
Ed Arce
Price Target
n/a
2025-03-18
Reiterates
Hold
Reason
Needham
Joseph Stringer
Strong Buy
to
Hold
Downgrades
$10
2025-03-04
Reason
Needham
Joseph Stringer
Price Target
$10
2025-03-04
Downgrades
Strong Buy
to
Hold
Reason
Wells Fargo
Tiago Fauth
Hold
Maintains
$4 → $3
2025-03-04
Reason
Wells Fargo
Tiago Fauth
Price Target
$4 → $3
2025-03-04
Maintains
Hold
Reason
Cantor Fitzgerald
Pete Stavropoulos
Hold
Initiates
n/a
2025-03-04
Reason
Cantor Fitzgerald
Pete Stavropoulos
Price Target
n/a
2025-03-04
Initiates
Hold
Reason
Cantor Fitzgerald reinstated coverage of Pliant Therapeutics with a Neutral rating and no price target. The company is discontinuing the Pase 2b BEACON-IPF study of bexotegrast in idiopathic pulmonary fibrosis, the analyst tells investors in a research note. The firm says that while Pliant has two additional clinical stage programs and a third Phase 1-ready asset, without clear visibility on program prioritization, it remains on the sidelines.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pliant Therapeutics Inc (PLRX.O) is -0.82, compared to its 5-year average forward P/E of -5.14. For a more detailed relative valuation and DCF analysis to assess Pliant Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.14
Current PE
-0.82
Overvalued PE
-1.83
Undervalued PE
-8.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.69
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.36
Undervalued EV/EBITDA
-5.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
300.88
Current PS
0.00
Overvalued PS
590.51
Undervalued PS
11.25
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 138.46% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PLRX News & Events

Events Timeline

(ET)
2025-12-04
07:40:00
Pliant Therapeutics Announces Interim Data from PLN-101095 Clinical Trial
select
2025-11-06 (ET)
2025-11-06
18:42:29
Pliant Therapeutics Announces Q3 Earnings Per Share of 43 Cents, Below Consensus Estimate of 52 Cents
select
2025-08-07 (ET)
2025-08-07
17:39:15
Pliant Therapeutics reports Q2 EPS (71c), consensus (68c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
02:53 AMBenzinga
Combination of Pliant Cancer Drug and Merck's Keytruda Enhances Treatment Responses in Challenging Tumors

  • Pliant Therapeutics' Trial Results: Pliant Therapeutics released promising interim data from its Phase 1 trial of PLN-101095, showing antitumor activity in combination with Merck's Keytruda in patients with advanced solid tumors that are refractory to immune checkpoint inhibitors.

  • Clinical Responses Observed: Among the heavily pretreated patient population, there were four responders, including one complete response and three partial responses, with clinical responses noted in various cancer types such as cholangiocarcinoma and melanoma.

  • IFN-γ Levels and Tolerability: Responding patients exhibited significant increases in plasma interferon gamma levels, while PLN-101095 was generally well tolerated, demonstrating a dose-dependent pharmacokinetic profile.

  • Stock Performance and Future Plans: Despite the positive trial results, Pliant's stock fell by over 20%, trading near its 52-week low, while the company plans to initiate a Phase 1b trial in 2026 to further explore PLN-101095's efficacy in non-small cell lung cancer and other tumor types.

[object Object]
Preview
4.0
10-10Benzinga
JP Morgan Lowers Pliant Therapeutics Rating to Underweight

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to help them make informed decisions in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
2.0
09-10NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading Following Trial News, Insider Purchases, and Conference Excitement

  • Biotech Stock Movements: Several small- and mid-cap biotech stocks experienced significant gains in after-hours trading on September 9, 2025, driven by clinical updates, insider buying, and upcoming investor conferences, with notable performances from Immutep, Nautilus Biotechnology, and Pliant Therapeutics.

  • Immutep's Clinical Trial Update: Immutep's shares rose 4.37% after announcing that data from its Phase II trial for eftilagimod alpha will be presented at the CTOS 2025 conference, focusing on a rare cancer with high unmet need.

  • Nautilus Biotechnology Insider Buying: Nautilus Biotechnology's stock surged 12.25% following CEO Sujal M. Patel's significant insider purchases, indicating confidence in the company's future, alongside participation in an upcoming investor conference.

  • Kura Oncology's Regulatory Milestones: Kura Oncology's shares increased 6.12% after presenting at the H.C. Wainwright conference, highlighting key developments and upcoming regulatory milestones for its menin inhibitor targeting acute myeloid leukemia.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pliant Therapeutics Inc (PLRX) stock price today?

The current price of PLRX is 1.31 USD — it has decreased -14.94 % in the last trading day.

arrow icon

What is Pliant Therapeutics Inc (PLRX)'s business?

Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

arrow icon

What is the price predicton of PLRX Stock?

Wall Street analysts forecast PLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLRX is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pliant Therapeutics Inc (PLRX)'s revenue for the last quarter?

Pliant Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Pliant Therapeutics Inc (PLRX)'s earnings per share (EPS) for the last quarter?

Pliant Therapeutics Inc. EPS for the last quarter amounts to -0.43 USD, decreased -54.74 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pliant Therapeutics Inc (PLRX)'s fundamentals?

The market is revising Upward the revenue expectations for Pliant Therapeutics, Inc. (PLRX) for FY2025, with the revenue forecasts being adjusted by 11.11% over the past three months. During the same period, the stock price has changed by -29.57%.
arrow icon

How many employees does Pliant Therapeutics Inc (PLRX). have?

Pliant Therapeutics Inc (PLRX) has 171 emplpoyees as of December 05 2025.

arrow icon

What is Pliant Therapeutics Inc (PLRX) market cap?

Today PLRX has the market capitalization of 80.50M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free